Recce Pharmaceuticals
Level 34, 50 Bridge Street
AMP Centre
Sydney
New South Wales
2000
Australia
Tel: 61-2-8216-0768
Website: http://www.recce.com.au/
Email: peter.williams@recce.com.au
About Recce Pharmaceuticals
Recce Ltd is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.
YEAR FOUNDED:
2007
LEADERSHIP:
Founder: Graham JH Melrose
CFO: Peter Williams
CLINICAL TRIAL:
107 articles about Recce Pharmaceuticals
-
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
4/17/2024
Recce Pharmaceuticals Ltd today announced the successful batch completion under Good Manufacturing Practices (GMP) for its lead candidate, RECCE® 327 (R327), with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.
-
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
4/10/2024
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced its selection by the United Kingdom’s Government Innovation Agency to partake in the prestigious UK Antimicrobial Resistance Inward Mission 2024.
-
Recce Pharmaceuticals Provides Business Update - April 10, 2024
4/10/2024
Recce Pharmaceuticals Ltd, a leading developer of a new class of synthetic anti-infectives, provided a business update highlighting various ongoing activities and progress made since the Annual General Meeting held on November 8, 2023.
-
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
4/4/2024
Recce Pharmaceuticals Ltd today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
-
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
3/22/2024
Recce Pharmaceuticals Ltd today announced it has been issued a trademark registration for RECCE ® from the Canadian Intellectual Property Office, strengthening its global intellectual property (IP) portfolio.
-
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
3/19/2024
Recce Pharmaceuticals Ltd today announced it completed dosing healthy subjects in the latest cohort of its Phase I/II trial, evaluating its lead candidate, RECCE ® 327 (R327).
-
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
3/14/2024
Recce Pharmaceuticals Ltd today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).
-
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
3/13/2024
Recce Pharmaceuticals Ltd announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.
-
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
3/12/2024
Recce Pharmaceuticals Ltd announced it received AUD $11,178,965 as a research and development advance with Endpoints Capital, capturing Recce’s R&D tax incentive for the 2023/2024 fiscal year and 2025 fiscal year.
-
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
2/29/2024
Recce Pharmaceuticals Ltd announced the continuation of work within its Anti-Infective Research Unit at the Murdoch Children’s Research Institute, to streamline its ongoing preclinical programs while investigating new indications for future clinical trials.
-
Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections
2/27/2024
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced the expansion of its ongoing Phase I/II trial evaluating the safety and efficacy of its lead candidate, RECCE® 327 (R327), in patients with diabetic foot infections (DFI) based on the interim data analysis and the study achieving its primary endpoints.
-
Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program
2/7/2024
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-Infectives, today announced it signed a Memorandum of Understanding (MoU) with PT Etana Biotechnologies, a leading Indonesian biomedical organization, to accelerate the clinical development of Recce’s anti-infective portfolio across Indonesia.
-
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
1/23/2024
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I/II trial assessing the safety and efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), in patients with diabetic foot infections (DFI).
-
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
12/19/2023
Recce Pharmaceuticals Ltd announced it was awarded an Advanced Overseas Finding for $43,774,907 of a synthetic antibiotic Research & Development applicable expenditure by AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.
-
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea
12/18/2023
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company) today announced positive preclinical results from an in vivo study evaluating the antibacterial efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), against Neisseria gonorrhoeae (N. gonorrhoeae) in a mouse vaginal infection model.
-
Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives
11/27/2023
Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
-
Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
11/9/2023
Recce Pharmaceuticals Ltd today announced it completed dosing the first healthy subjects at the highest concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327).
-
Recce Pharmaceuticals Announces Safety Committee Approves Faster Infusion Rate in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
10/25/2023
Recce Pharmaceuticals Ltd today announced an Independent Safety Committee has approved the next cohort dosing at a faster infusion rate of 15 minutes of 3,000mg in a Phase I/II clinical trial evaluating its lead anti-infective candidate, RECCE® 327.
-
Recce Pharmaceuticals Announces Results of Entitlement Offer - October 03, 2023
10/3/2023
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced the completion of an entitlement offer to shareholders raising approximately $2.7 million before costs.
-
Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of RECCE® 327 for Urinary Tract Infections
9/26/2023
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced it completed cohort dosing of healthy male and female subjects in its Phase I/II clinical trial evaluating its lead anti-infective candidate, RECCE® 327 (R327), at faster infusion rates.